Prostate cancer is among the most prevalent malignancies in men. 68Ga-PSMA PET-CT has revolutionized urological oncology by providing receptor-targeted precision.
Receptor-Specific Targeting binds to PSMA overexpressed on 90%+ of prostate cancer cells. Ultra-Low PSA Detection even at 0.2 to 0.5 ng/mL.